PubMed:27149138 / 7423-7591 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T72","span":{"begin":0,"end":168},"obj":"Sentence"},{"id":"T72","span":{"begin":0,"end":168},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Patients with UC treated with infliximab plus AZA were more likely to achieve corticosteroid-free remission at 16 weeks than those receiving either monotherapy (10,12)."}

{"project":"Inflammaging","denotations":[{"id":"T72","span":{"begin":0,"end":168},"obj":"Sentence"},{"id":"T72","span":{"begin":0,"end":168},"obj":"Sentence"}],"text":"Patients with UC treated with infliximab plus AZA were more likely to achieve corticosteroid-free remission at 16 weeks than those receiving either monotherapy (10,12)."}